Literature DB >> 16732210

Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy.

A Berenbom1, R M Davila, H-S Lin, J W Harbour.   

Abstract

PURPOSE: Intravitreal chemotherapy for primary intraocular lymphoma (PIOL) increasingly is promoted as an alternative to radiotherapy, owing to putative high failure and complication rates of the latter modality. Our aim was to confirm whether these concerns about radiotherapy were borne out in patients treated at our institution over the last decade.
DESIGN: Retrospective interventional case series. PARTICIPANTS: A total of 21 eyes of 12 patients with PIOL.
METHODS: Comprehensive chart review of ophthalmologic and systemic manifestations, treatments, and outcomes. MAIN OUTCOME MEASURES: Radiation complications and local tumour control.
RESULTS: Cytology-confirmed lymphoma involved one eye in three patients and both eyes in nine patients. Initial treatment included external beam radiotherapy and chemotherapy (six patients), chemotherapy alone (four patients), radiotherapy alone (one patient), and no treatment (one patient). Ocular relapses occurred in no patients receiving radiotherapy and in two patients who did not receive radiotherapy. Complications of radiotherapy included dry eye (four patients), cataract (four patients), and mild radiation retinopathy (two patients).
CONCLUSIONS: Radiotherapy for PIOL is highly effective with acceptable complications. In the absence of a clear advantage to intravitreal chemotherapy, which involves repetitive injections and associated risks, radiotherapy may still be the most appropriate first-line treatment in most cases.

Entities:  

Mesh:

Year:  2006        PMID: 16732210     DOI: 10.1038/sj.eye.6702437

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  23 in total

Review 1.  Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.

Authors:  Chi-Chao Chan; James L Rubenstein; Sarah E Coupland; Janet L Davis; J William Harbour; Patrick B Johnston; Nathalie Cassoux; Valerie Touitou; Justine R Smith; Tracy T Batchelor; Jose S Pulido
Journal:  Oncologist       Date:  2011-11-01

2.  Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy.

Authors:  James L Rubenstein; Patrick A Treseler; Paul J Stewart
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

Review 3.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

Review 4.  The Challenge of Primary Central Nervous System Lymphoma.

Authors:  Julia Carnevale; James L Rubenstein
Journal:  Hematol Oncol Clin North Am       Date:  2016-12       Impact factor: 3.722

5.  [Diagnostics and treatment of primary vitreoretinal lymphoma].

Authors:  N Stübiger; V Kakkassery; E Gundlach; S Winterhalter; U Pleyer
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

Review 6.  Intraocular lymphoma.

Authors:  Li-Juan Tang; Chang-Lin Gu; Ping Zhang
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

Review 7.  Diagnosis and treatment of primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937

8.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

9.  Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function.

Authors:  M Hata; I Koike; J Maegawa; A Kaneko; K Odagiri; T Kasuya; Y Minagawa; H Kaizu; Y Mukai; T Inoue
Journal:  Strahlenther Onkol       Date:  2012-10-28       Impact factor: 3.621

10.  Ophthalmic manifestations, cytology, immunohistochemistry, and molecular analysis of intraocular metastatic T-cell lymphoma: report of a case and review of the literature.

Authors:  Grace A Levy-Clarke; David Greenman; Pamela C Sieving; Gordon Byrnes; Defen Shen; Robert Nussenblatt; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2008 May-Jun       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.